KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Amneal Pharmaceuticals (AMRX) Non Operating Income (2017 - 2026)

Amneal Pharmaceuticals has reported Non Operating Income over the past 9 years, most recently at $13.2 million for Q4 2025.

  • For Q4 2025, Non Operating Income rose 104.19% year-over-year to $13.2 million; the TTM value through Dec 2025 reached -$44.7 million, up 88.01%, while the annual FY2025 figure was $16.5 million, 105.43% up from the prior year.
  • Non Operating Income for Q4 2025 was $13.2 million at Amneal Pharmaceuticals, up from $1.2 million in the prior quarter.
  • Over five years, Non Operating Income peaked at $155.2 million in Q4 2023 and troughed at -$313.9 million in Q4 2024.
  • A 5-year average of -$36.9 million and a median of -$15.2 million in 2021 define the central range for Non Operating Income.
  • On a YoY basis, Non Operating Income climbed as much as 606.13% in 2021 and fell as far as 4997.79% in 2021.
  • Year by year, Non Operating Income stood at -$130.0 million in 2021, then dropped by 29.16% to -$168.0 million in 2022, then surged by 192.42% to $155.2 million in 2023, then crashed by 302.24% to -$313.9 million in 2024, then surged by 104.19% to $13.2 million in 2025.
  • Business Quant data shows Non Operating Income for AMRX at $13.2 million in Q4 2025, $1.2 million in Q3 2025, and -$59.7 million in Q2 2025.